By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Huntsman Corporation (HUN), with key concerns being the structural supply glut, persistent cyclicality, and the risk of prolonged weak demand. The panelists also flagged high debt levels, working-capital volatility, and the potential for structurally lower margins due to shifting supply chains.
Risk: The single biggest risk flagged is the structural supply glut from Chinese and Middle Eastern capacity additions, which continues to pressure polyurethane and performance products margins well beyond typical cycles.
Opportunity: No significant opportunities were highlighted by the panel.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Is HUN a good stock to buy? We came across a bullish thesis on Huntsman Corporation on Hidden Rock Capital's Newsletter’s Substack by Hidden Rock Capital. In this article, we will summarize the bulls’ thesis on HUN. Huntsman Corporation's share was trading at $14.23 as of June 8th. HUN’s forward P/E was 1.00k according to Yahoo Finance.
Syda Productions/Shutterstock.com
Huntsman Corporation (HUN) is a specialty chemicals producer operating across three core segments, including Polyurethanes used in insulation, foam, sealants, and construction applications, Performance Products serving industrial, automotive, and electronics end markets, and Advanced Materials focused on high-performance adhesives, composites, and coatings.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company has faced a prolonged cyclical downturn, with its stock declining more than 50% over the past five years as weak end-market demand, post-COVID inventory destocking, and significant new capacity additions from China and the Middle East have weighed on pricing and margins across the chemicals industry. Despite these headwinds, Huntsman’s underlying business model remains structurally intact, with its diversified exposure across industrial value chains and historically resilient cash generation through the cycle.
The investment case centers on the extreme cyclicality of earnings, where Huntsman’s adjusted EBITDA has fluctuated sharply across multiple business cycles, including strong boom periods in 2016–2018 and 2021–2022, and weaker downturns in 2019–2020 and the ongoing post-2023 trough.
Over the past decade, the company has still averaged approximately $800–$900 million in mid-cycle adjusted EBITDA, suggesting current results reflect cyclical compression rather than long-term deterioration. This normalization supports a view that earnings are well below potential, with significant embedded operating leverage if global industrial demand stabilizes and supply-demand conditions tighten.
Applying a mid-cycle valuation framework using an 8–10x EV/EBITDA multiple, in line with historical specialty chemical market ranges, implies a fair value of approximately $30–$40 per share. This represents a potential upside of roughly 3x from the current ~$13 share price, highlighting a compelling risk-reward skew. In a recovery scenario where volumes normalize and pricing power improves, Huntsman could experience both earnings expansion and multiple rerating, positioning the stock as a high-beta cyclical recovery opportunity with meaningful upside optionality from mean reversion in global chemical markets.
Four leading AI models discuss this article
"Ongoing Chinese capacity additions make sustained mid-cycle EBITDA normalization unlikely within the next two to three years."
The bullish case for HUN rests on mean-reversion to $800-900M mid-cycle EBITDA and an 8-10x EV/EBITDA multiple, implying $30-40 fair value. Yet the article underplays the structural supply glut: Chinese and Middle Eastern capacity additions continue to pressure polyurethane and performance products margins well beyond typical cycles. Huntsman’s own history shows EBITDA can stay depressed for multiple years once new supply enters. At current ~$13-14 prices the stock already prices in a shallow recovery; any delay in global industrial demand or further Chinese export surges could keep earnings near trough levels into 2026, eroding the 3x upside thesis.
Even with persistent overcapacity, a sudden global manufacturing rebound could still lift volumes enough for a 50-70% re-rating before structural issues fully bite.
"The upside hinges on an uncertain macro-driven mid-cycle rebound; without it, the proposed 3x upside from today is speculative."
The article hinges on a mid-cycle EBITDA normalization (roughly $800–$900m) and an 8–10x EV/EBITDA multiple to justify a $30–$40 fair value, implying ~3x upside from ~$13. However, this glosses over persistent cyclicality, the risk of prolonged weak demand, and continued raw-material and energy-cost volatility that can keep margins under pressure. The claim of a 1,000x forward P/E appears erroneous and undermines credibility. Structural overcapacity from PU in China/MME, plus ongoing capex needs and working-capital swings, could delay any re-rating and depress FCF, especially if demand rebound lags or tariff/trade dynamics worsen.
Even if a rebound occurs, it may take longer than expected, and the credit-like spread between EBITDA normalization and cash flow could widen due to capex and working capital, challenging the assumed upside. Also, the article’s 1,000x forward P/E claim looks like a data error, casting doubt on the bullish setup.
"The thesis assumes cyclical mean reversion, but ignores that structural overcapacity in the Asian chemical market has permanently impaired HUN's historical pricing power."
The thesis relies on a mid-cycle mean reversion that ignores the structural shift in global chemical supply. While HUN’s Polyurethanes segment is essential, the article glosses over the permanent capacity expansion in China, which has fundamentally lowered the floor for pricing power. A forward P/E of 1,000x is a glaring red flag indicating earnings are currently near zero, not just 'compressed.' While the 8-10x EV/EBITDA valuation is theoretically sound for a healthy specialty chemical firm, it assumes a macro recovery that may not materialize given sustained high interest rates impacting construction and automotive end-markets. HUN is a classic value trap until we see actual volume growth, not just hopeful math.
If global interest rates decline, the resulting surge in residential construction and automotive demand could trigger a rapid, violent snap-back in margins that the market is currently pricing at zero.
"The upside case hinges entirely on whether this is a temporary cyclical trough or a structural shift in global chemical supply-demand dynamics; the article provides no evidence to distinguish between them."
The thesis rests on cyclical mean reversion: HUN trades at ~$14 with a nonsensical 1.00k forward P/E (likely a data error), and bulls argue mid-cycle EBITDA of $800–900M justifies $30–40 fair value at 8–10x EV/EBITDA. The case is mechanically sound IF we accept three premises: (1) current demand trough is temporary, not structural; (2) Chinese/Middle Eastern capacity won't permanently depress margins; (3) HUN's balance sheet survives the cycle. The article ignores debt levels, capex requirements, and whether 'mid-cycle' EBITDA is achievable in a slower-growth world. Cyclicals work until they don't—timing matters enormously.
If China's polyurethane and specialty chemical capacity remains structurally oversupplied for years (not months), or if industrial demand stays depressed longer than the 2016–2018 cycle suggests, HUN could be a value trap—not a recovery play—with further downside before any rerating.
"Elevated debt and capex could force asset sales, prolonging the trough beyond historical cycles."
Claude flags the three premises but understates how HUN's $2B+ net debt plus $300M annual capex could force asset sales or dilution if EBITDA lingers below $500M into 2025. This directly compounds ChatGPT's FCF warning: even a modest volume uptick fails to deleverage before fresh Chinese capacity hits. The 2016-18 cycle analogy collapses under today's rates, which extend troughs rather than shorten them.
"Deleveraging risk hinges more on cash-flow timing than on EBITDA alone."
To Grok: asset sales aren't the only lever, but they're a slow, painful path; debt could be managed via cash flow and reorganized capex. The bigger risk you're missing is working-capital volatility and its drag on FCF when volumes lag. Even with EBITDA reviving, WC swings can slow deleveraging, capping upside unless HUN stabilizes collections and reduces capital intensity. Deleveraging risk hinges more on cash-flow timing than on EBITDA alone.
"Huntsman's structural margin compression in Performance Products renders historical EV/EBITDA multiples obsolete, even if MDI volumes recover."
Grok and ChatGPT are missing the secondary impact of HUN's portfolio composition. The focus on MDI (methylene diphenyl diisocyanate) ignores the 'Performance Products' drag, which is structurally impaired by shifting supply chains, not just cyclicality. Even if MDI volumes recover, the margin profile of the remaining business will likely settle structurally lower than historical averages. Relying on a 10x EV/EBITDA multiple is overly optimistic when the firm's ROIC is trending toward its cost of capital.
"ROIC deterioration is the hidden kill-switch for the recovery thesis, but nobody has the actual numbers to confirm it."
Gemini's ROIC-toward-cost-of-capital point is critical but needs quantification. If HUN's ROIC is genuinely collapsing below WACC (~7-8%), the 10x multiple isn't just optimistic—it's indefensible, and the firm destroys shareholder value even at $30. But the article provides no ROIC data. Without knowing whether current depressed EBITDA masks structurally broken unit economics or just cyclical margin compression, we're valuing on hope, not fundamentals. That's the real trap.
The panel consensus is bearish on Huntsman Corporation (HUN), with key concerns being the structural supply glut, persistent cyclicality, and the risk of prolonged weak demand. The panelists also flagged high debt levels, working-capital volatility, and the potential for structurally lower margins due to shifting supply chains.
No significant opportunities were highlighted by the panel.
The single biggest risk flagged is the structural supply glut from Chinese and Middle Eastern capacity additions, which continues to pressure polyurethane and performance products margins well beyond typical cycles.